Other languages Noxopharm Limited

Equities

NOX

AU000000NOX9

Market Closed - Australian S.E. Other stock markets 23:57:59 2024-05-01 EDT			5-day change	1st Jan Change
0.06 ^AUD	-11.76%		-6.25%	-15.49%

04-04	Noxopharm Receives AU$100,000 to Progress Brain Cancer Drug	MT
02-27	Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive	02-27
Noxopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-26
Noxopharm Extends Strategic Partnership with Hudson Institute of Medical Research	02-12
Noxopharm Receives AU$6.1 Million R&D tax Rebate; Shares Up 8%	11-15
Concerns of Further US Monetary Tightening Push Australian Shares to Nearly 11-Month Low	23-10-04
US FDA Grants Orphan Drug Status to Noxopharm's Pancreatic Cancer Drug; Shares Surge 73%	23-10-04
Noxopharm Validates Efficacy of Cancer Treatment in Animal Study; Shares Rally 13%	23-09-28
Noxopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31
NobleOak Life Secures Approval from Financial Services Regulator for Reporting Standards	23-07-03
Study Finds Noxopharm's New SOF-XX Drug Reduces Inflammation	23-05-19
Noxopharm's NOXO Options to Expire June 18; Shares Down 17%	23-05-08
Noxopharm to Discontinue Veyonda Trials; to Focus on Chroma, Sofra Platforms; Shares Plummet 41%	23-04-06
Noxopharm to Develop Vaccine Enhancer; Shares Rise 3%	23-03-27
Noxopharm Limited Announces Novel mRNA Vaccine Enhancer	23-03-27
Noxopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23
Noxopharm Limited to Present Sofra Study at Lupus 2023 Conference	23-02-21
Noxopharm Advances to the Efficacy Portion of its Phase 2 Prostate Cancer Trial	23-01-17
Noxopharm Limited Reviews Safety Data from the Third Cohort of Patients from the Dose Escalation Part of the DARRT-2 Trial	23-01-16
Noxopharm Receives Innovation Connections Grant; Shares Fall 5%	22-12-05
Noxopharm Advances Phase 1 Cancer Drug Trial Following Safety Clearance	22-12-02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Noxopharm Limited

Equities

NOX

AU000000NOX9

Other languages

Filters